Results 21 to 30 of about 2,106 (155)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis

Journal of the Formosan Medical Association, 2008
Darbepoetin alfa can be administered less frequently than recombinant human erythropoietin (r-HuEPO) for the treatment of anemia in chronic renal failure (CRF) patients.
Wen-Yi Li, Tzong-Shinn Chu, Jenq-Wen Huang, Ming-Shiou Wu, Kwan-Dun Wu   +4 more
doaj   +1 more source

Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. [PDF]

PLoS ONE, 2010
BackgroundErythropoiesis stimulating agents (ESAs) are widely used to treat anaemia but concerns exist about their potential to promote pathological angiogenesis in some clinical scenarios.
Carmel M McVicar, Liza M Colhoun, Jodie L Abrahams, Claire L Kitson, Ross Hamilton, Reinhold J Medina, Dash Durga, Tom A Gardiner, Pauline M Rudd, Alan W Stitt   +9 more
doaj   +1 more source

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease

Indian Journal of Transplantation, 2018
Introduction: The present study compared the efficacy, safety, and immunogenicity of the biosimilar darbepoetin alfa to the reference innovator darbepoetin alfa in the treatment of anemia in chronic kidney disease (CKD) patients.
Prasad Apsangikar, Sunil Chaudhry, Manoj Naik, Shashank Deoghare, Jamila Joseph   +4 more
doaj   +1 more source

The effect of darbepoetin alfa on the glomerulus of new-born mice with intrauterine growth restriction [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Intrauterine growth restriction is a condition in which a fetus is not able to achieve its genetic potential for growth. It has been linked with diseases of adulthood, such as hypertension, insulin-independent diabetes mellitus ...
Milojković Milica, Stojanović Vesna, Barišić Nenad   +2 more
doaj   +1 more source

Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients

Медицинский совет, 2021
Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign.
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova   +2 more
doaj   +1 more source

Extended dosing of darbepoetin alfa in peritoneal dialysis patients

BMC Nephrology, 2011
Background Anemia is common among peritoneal dialysis (PD) patients, and most patients require erythropoiesis-stimulating agents (ESA) to maintain their hemoglobin concentrations within current guideline recommendations. Darbepoetin alfa is an ESA with a
Bridges Ian, Rottembourg Jacques B, McMahon Lawrence P, De Meester Johan MJ, Feriani Mariano, Farouk Mourad, Pronai Wolfgang   +6 more
doaj   +1 more source

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

BMC Cancer, 2010
Background Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients by ...
Silberstein Peter, Rearden Timothy, Mirtsching Barry, Burkes Ronald, Schwartzberg Lee, Yee Lorrin, Inamoto Amy, Lillie Tom   +7 more
doaj   +1 more source

CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS

Український Журнал Нефрології та Діалізу, 2015
The article describes the ways to cost optimization of anemia treatment CKD - HD patients. Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA). Methods.
M. Kolesnyk, N. Bezdetko, V. Novakivskyy
doaj   +1 more source

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2022
Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the evidence for vadadustat in the treatment of CKD patients with anemia ...
Limei Xiong, Limei Xiong, Hui Zhang, Yannan Guo, Yue Song, Yue Song, Yuhong Tao, Yuhong Tao, Yuhong Tao   +8 more
doaj   +1 more source

A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient

Allergy, Asthma & Clinical Immunology, 2018
Background Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need for desensitization are rare.
Jaime S. Rosa, Van B. Vuong, Orly Haskin, Anne Y. Liu   +3 more
doaj   +1 more source